Impact of the number of repeated inhalations and patient characteristics on the residual amount of inhaled laninamivir octanoate hydrate dry powder in pediatric patients with influenza

BACKGROUND: A dry powder inhaled formulation is used for the anti-influenza drug laninamivir octanoate hydrate (laninamivir). Although two successive inhalations (puffs) are recommended to minimize residual amounts of active ingredients, previous reports suggest that pediatric patients with low peak...

Descripción completa

Detalles Bibliográficos
Autores principales: Murasaka, Toshiki, Ikemura, Kenji, Enokiya, Tomoyuki, Muraki, Yuichi, Ikemura, Mayumi, Terada, Koji, Iwamoto, Takuya, Okuda, Masahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678805/
https://www.ncbi.nlm.nih.gov/pubmed/29152321
http://dx.doi.org/10.1186/s40780-017-0094-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678805/
https://www.ncbi.nlm.nih.gov/pubmed/29152321
http://dx.doi.org/10.1186/s40780-017-0094-7

Ejemplares similares